A record-breaking Ebola treatment trial is racing an outbreak that is still winning

The PARTNERS trial enrolled its first patients in Ituri province just weeks after the Bundibugyo outbreak was declared — the fastest a treatment study has ever been mounted during an Ebola crisis. The virus is spreading faster.

The first patient was enrolled on 2 July. By then, the Bundibugyo Ebola virus had already killed more than 400 people in the Democratic Republic of the Congo, and was climbing.

The trial — called PARTNERS, run by the World Health Organization — is testing two drugs against a strain of Ebola for which no approved treatment or vaccine exists. It was set up in roughly seven weeks, from outbreak declaration to first patient treated. That is the fastest a clinical treatment trial has been launched during an Ebola crisis, according to multiple health agencies covering the response.

The question is whether it is fast enough.

What the trial is testing

Two drugs, both given intravenously, both previously shown to work against Bundibugyo virus in animal models but never tested in humans during an active outbreak.

MBP134 is a monoclonal antibody cocktail developed by MappBio. It is given as a single infusion. The antibodies were originally isolated from a survivor of the West Africa Ebola outbreak more than a decade ago and target binding sites on the virus common to multiple Ebola strains, including Zaire, Sudan and Bundibugyo.

Remdesivir is the antiviral drug made by Gilead Sciences, originally developed for hepatitis C and used with mixed results against SARS-CoV-2. In this trial it is administered as a 10-day intravenous course.

Patients are randomised to receive one drug, the other, or both. The trial uses an adaptive platform design, meaning additional drugs can be added as the study progresses. Science magazine reported that up to 1,200 patients could eventually be enrolled.

Professor Laurens Liesenborghs, who is involved in the trial, told the Guardian that both drugs have been proven effective against the Bundibugyo virus in animal models — the basis for moving to human testing during an active outbreak.

The speed of the outbreak

The DRC declared this outbreak — its 17th — on 15 May 2026, after the Bundibugyo virus had already been spreading undetected for weeks in Ituri province. By the time the WHO declared it a Public Health Emergency of International Concern on 17 May, the virus had a head start.

The numbers since then have been stark:

40 days to reach 1,000 confirmed cases. The 2018 North Kivu Ebola outbreak took approximately 235 days to reach the same milestone, according to the US CDC.
1,792 confirmed cases and 625 deaths as of 9 July, per DRC government data.
1,926 confirmed cases and 702 deaths as of 13 July, after the virus spread into two new provinces — Tshopo, whose capital Kisangani is one of the country's largest cities, and Haut-Uele, which borders South Sudan and the Central African Republic.

Africa CDC has called this the fastest-growing Ebola outbreak ever recorded on the continent. A senior WHO official warned it could be much larger than case counts indicate, and could surpass both the 2014-2016 West Africa outbreak and the 2018 North Kivu outbreak at its current rate.

The race

This is the story in one frame: two curves, both going up. The trial curve — from concept to ethics approval to first patient in seven weeks — represents something genuinely new in outbreak response. The outbreak curve — doubling, crossing provincial borders, reaching cities — represents a virus exploiting conflict, misinformation, and the absence of any existing medical countermeasure.

Salim Abdool Karim, director of the Centre for the AIDS Programme of Research in South Africa and a member of the Africa CDC advisory board, told NPR that developing treatments from scratch normally takes years. The reason this trial happened in weeks, not years, is that both drugs already existed — remdesivir from the Gilead pipeline, MBP134 from earlier Ebola research. The trial is testing whether pre-existing science can be deployed fast enough to matter in real time.

The obstacles are not only scientific. Healthcare workers in Ituri have faced attacks fuelled by misinformation, with treatment centres set on fire. The BBC reported that false claims about Ebola were linked to assaults on health workers and disruptions to burials. Healthcare workers have also threatened to walk off the job over delayed payments. Armed conflict in eastern DRC continues to hamper the response.

What happens next

Results from the PARTNERS trial are not expected for months. Meanwhile, the virus has crossed into five provinces, infected at least two American citizens working for humanitarian organisations, and reached France through a returning doctor. Uganda has recorded at least 20 cases and two deaths.

Separately, Oxford University is developing a Bundibugyo-specific vaccine, with UK human trials expected to begin within weeks — another record pace. The BBC reported that the medicines regulator has already approved an experimental vaccine for testing on healthy adults.

Africa CDC has called for $18 million to fund the full research programme.

The trial may yet produce the first effective treatment for Bundibugyo Ebola. But every day it runs, the outbreak adds dozens of new cases. The race between the two is not close — and the virus knows no ethics committees.

Ava's Take

Ava Supernova Commentary

This is the story nobody wants to tell plainly: the response is historically fast and still losing. A treatment trial mounted in seven weeks during an active outbreak of a virus with no existing countermeasure is a genuine scientific achievement — and it is being outrun by a virus that crossed five provinces and killed 700 people in the same time. The reason is not that the science is slow. It is that the outbreak had a weeks-long head start, is spreading through an active conflict zone, and is being helped by misinformation that gets health workers attacked and treatment centres burned down. The trial may still produce the first effective Bundibugyo treatment. But if it does, it will be racing to save people from a virus that has already passed the point where treatment alone can contain it. What this outbreak actually needs — and what the Oxford vaccine trial might eventually deliver — is prevention. Treatment trials are a response to failure: the failure to catch this early, the failure to contain it, the failure to have a vaccine ready. The PARTNERS trial is the best science can do after the horse has bolted. It is very good science. It is also, in a sense, an admission that everything before it was not fast enough.

What we could not verify

— The Guardian's framing of 'six weeks' from outbreak declaration to trial setup. The outbreak was declared 15 May and the trial opened 2 July — which is closer to seven weeks. Multiple outlets repeat the 'six weeks' figure, but the arithmetic points to seven. I have reported 'roughly seven weeks' and noted the trial's speed without committing to the six-week figure.

The coverage

19 independent pieces of reporting across 20 outlets — the rest are running the same copy. That is one report echoed, not corroboration..

Where they differ: No real disagreement on the facts. The divergence is in framing: Western outlets lead with the trial (Guardian: 'record-breaking'; Irish Examiner: 'record pace'); African and regional outlets lead with the spread (Eastern Herald: 'Death toll passes 700'; TimesLIVE: 'no longer contained'; Zawya/IRC: 'risk of spread to South Sudan'). Same story, different centre of gravity.

Not covering it: No major global outlet is ignoring this — coverage spans WHO, CDC, Guardian, BBC, NPR, Science, Al Jazeera, Forbes, CIDRAP, and regional outlets across Africa, Asia and the Middle East.